Affluent Medical SAS Total Liabilities

Latest as of June 2025: €38.73 Million EUR ≈ $45.28 Million USD

Affluent Medical SAS total liabilities. Based on the latest financial reports, Affluent Medical SAS (AFME) has total liabilities worth €38.73 Million EUR (≈ $45.28 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check AFME financial resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Affluent Medical SAS (2016–2024)

Total liabilities of Affluent Medical SAS from 2016 to 2024. This chart illustrates how Affluent Medical SAS's total liabilities have evolved over time, based on quarterly financial data.

Affluent Medical SAS Competitors by Total Liabilities

The table below lists competitors of Affluent Medical SAS ranked by their total liabilities.

Company Country Total Liabilities
Cape Industries Ltd
KQ:064820
Korea ₩4.26 Trillion
ADTechnology Co.Ltd
KQ:200710
Korea ₩157.56 Billion
HB Technology CO.LTD
KQ:078150
Korea ₩92.24 Billion
Nelly Group AB
ST:NELLY
Sweden Skr547.40 Million
GMM Grammy Public Company Limited
BK:GRAMMY
Thailand ฿3.17 Billion
Takarék Jelzálogbank Nyrt
F:FH21
Germany €682.66 Billion
Poh Kong Holdings Bhd
KLSE:5080
Malaysia RM407.48 Million
Butterfly Gandhimathi Appliances Limited
NSE:BUTTERFLY
India Rs2.09 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down Affluent Medical SAS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see AFME total asset value.

Liquidity & Leverage Metrics

Affluent Medical SAS Total Liabilities Ratios Explained

Affluent Medical SAS total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 1.07 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.83 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.65 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Affluent Medical SAS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Affluent Medical SAS (2016–2024)

The table below shows the annual total liabilities of Affluent Medical SAS from 2016 to 2024.

Year Total Liabilities Change
2024-12-31 €30.59 Million
≈ $35.76 Million
+21.61%
2023-12-31 €25.15 Million
≈ $29.40 Million
-3.96%
2022-12-31 €26.19 Million
≈ $30.62 Million
-1.18%
2021-12-31 €26.50 Million
≈ $30.98 Million
-10.28%
2020-12-31 €29.54 Million
≈ $34.53 Million
-13.86%
2019-12-31 €34.29 Million
≈ $40.09 Million
+471.56%
2017-12-31 €6.00 Million
≈ $7.01 Million
+110.20%
2016-12-31 €2.85 Million
≈ $3.34 Million
--

About Affluent Medical SAS

PA:AFME France Medical Devices
Market Cap
$129.10 Million
€110.43 Million EUR
Market Cap Rank
#18636 Global
#271 in France
Share Price
€2.81
Change (1 day)
+0.36%
52-Week Range
€1.33 - €2.81
All Time High
€8.30
About

Affluent Medical SA, a medical technology company, develops and markets minimally invasive minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardio… Read more